Pub Date : 2021-03-16DOI: 10.31031/nacs.2021.05.000623
Xiaomei Zhang
Percutaneous cryoablation is becoming a preferred option as one of the minimally invasive procedures in the management of tumor related cases due to its clearer visual field, promising anesthetic effect, perseverance of collagenous architecture as parts of its many advantages. In this case, a patient who was diagnosed with multiple pulmonary nodules with a high probability of malignancy, underwent this thermal ablative procedure. Lesions at the ablated zones viewed during the procedure are generally self-limiting, however, in our case ablated lesions which were marked by exudative infilitration and poor tissue healing persisted for over six months. The application of traditional Chinese medicine herbal treatment in this case was proven effective in managing such lesions, as well as its related signs and symptoms.
{"title":"A Case Report: Traditional Chinese Medicine Treatment in the Management of Exudative Infiltration Related to post-Cryoablation for Multiple Pulmonary Nodules","authors":"Xiaomei Zhang","doi":"10.31031/nacs.2021.05.000623","DOIUrl":"https://doi.org/10.31031/nacs.2021.05.000623","url":null,"abstract":"Percutaneous cryoablation is becoming a preferred option as one of the minimally invasive procedures in the management of tumor related cases due to its clearer visual field, promising anesthetic effect, perseverance of collagenous architecture as parts of its many advantages. In this case, a patient who was diagnosed with multiple pulmonary nodules with a high probability of malignancy, underwent this thermal ablative procedure. Lesions at the ablated zones viewed during the procedure are generally self-limiting, however, in our case ablated lesions which were marked by exudative infilitration and poor tissue healing persisted for over six months. The application of traditional Chinese medicine herbal treatment in this case was proven effective in managing such lesions, as well as its related signs and symptoms.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49375072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-11DOI: 10.31031/nacs.2021.05.000622
P. Lissoni
{"title":"How to Modulate the Immunoinflammatory Biological Response in Cancer, Autoimmunity and Viral Infections by a Psychoneuroimmune Approach","authors":"P. Lissoni","doi":"10.31031/nacs.2021.05.000622","DOIUrl":"https://doi.org/10.31031/nacs.2021.05.000622","url":null,"abstract":"","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43683267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-22DOI: 10.37421/2165-7831.2021.11.251
Á. Kellner, Vasana S Kellner, P. Rajnics, E. Karadi, Á. Illés, M. Udvardy, L. Homor, P. Dombi, J. Herczeg, Zoltán Sipiczki, Korom Viktória Győriné, M. Egyed
Objective: In our study we analysed thromboembolic (TE) events of ET patients using data from the Hungarian Myeloproliferative Neoplasm (HUMYPRON) registry. We examined possible thrombosis risk factors and compared Landolfi-, IPSET- and R-IPSET risk stratification models. Methods: The HUMYPRON registry was established in 2012 and contains data of patients from 14 Hungarian haematology centres. We analysed clinical and laboratory data of 237 ET (according to 2008 WHO classification) patients to assess possible risk factors of post-diagnostic TE events and to study the applicability of Landolfi-, IPSET- and R-IPSET thrombosis risk stratifications. Results: 237 ET patients were followed for median 10 years. After diagnosis 76 patients (32.1%) had TE complication. Previous thrombotic episode was found to be the only factor that had significant effect on TE events after diagnosis (p<0.001). On our sample R-IPSET proved to be the strongest model, where the frequency of TE events was 14.3% in the very low and 46% in the high risk patient group. Conclusions: During the follow-up period of median 10 years, prior TE event was the only factor that had highly significant effect on post-diagnostic thrombosis. Among the risk stratification systems R-IPSET model proved to be the strongest. Keywords: Essential Thrombocythemia | Thrombosis | Humypron Registry | Risk Factors | Thrombosis Risk Models
{"title":"Analysis of Thrombosis Risk Stratification Models Based on 10 Years Follow up of 237 Essential Thrombocythemia Patients","authors":"Á. Kellner, Vasana S Kellner, P. Rajnics, E. Karadi, Á. Illés, M. Udvardy, L. Homor, P. Dombi, J. Herczeg, Zoltán Sipiczki, Korom Viktória Győriné, M. Egyed","doi":"10.37421/2165-7831.2021.11.251","DOIUrl":"https://doi.org/10.37421/2165-7831.2021.11.251","url":null,"abstract":"Objective: \u0000In our study we analysed thromboembolic (TE) events of ET patients using data from the Hungarian Myeloproliferative Neoplasm (HUMYPRON) registry. We examined possible thrombosis risk factors and compared Landolfi-, IPSET- and R-IPSET risk stratification models. \u0000 \u0000Methods: \u0000The HUMYPRON registry was established in 2012 and contains data of patients from 14 Hungarian haematology centres. We analysed clinical and laboratory data of 237 ET (according to 2008 WHO classification) patients to assess possible risk factors of post-diagnostic TE events and to study the applicability of Landolfi-, IPSET- and R-IPSET thrombosis risk stratifications. \u0000 \u0000Results: \u0000237 ET patients were followed for median 10 years. After diagnosis 76 patients (32.1%) had TE complication. Previous thrombotic episode was found to be the only factor that had significant effect on TE events after diagnosis (p<0.001). On our sample R-IPSET proved to be the strongest model, where the frequency of TE events was 14.3% in the very low and 46% in the high risk patient group. \u0000 \u0000Conclusions: \u0000During the follow-up period of median 10 years, prior TE event was the only factor that had highly significant effect on post-diagnostic thrombosis. Among the risk stratification systems R-IPSET model proved to be the strongest. \u0000 \u0000Keywords: \u0000Essential Thrombocythemia | Thrombosis | Humypron Registry | Risk Factors | Thrombosis Risk Models","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45014021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-15DOI: 10.31031/nacs.2020.05.000619
B. K. Abdullah, Zainab Basil Kadhim, Ghada Basil Kadhim, Zena Jameeel Ahmed
Neuroblastoma is the most common malignancy in infancy and the third most common cancer in pediatric, following the acute leukemia and central nervous system tumor, constituting approximately 7-10% of pediatric malignancy. Most of the patients (approximately 90%) diagnosed before the age of 5 years, with peak incidence at the age of two years. However, the incidence of neuroblastoma decreasing with age and less than 5% from all cases diagnosed after the age of 10 years, its occurrence is rare during adulthood (one per 10 million cancer diagnoses per year). In addition, neuroblastoma is very rarely presented with Bone marrow involvement without identifiable primary site. We reported a young adult male patient with advanced neuroblastoma at the age of 21 with solely Bone marrow involvement without radiological identifiable primary tumor site who was died before starting him on chemotherapy treatment because of severe febrile neutropenia.
{"title":"Neuroblastom of the Bone Marrow in Young Adult Male Without Identifiable Primary","authors":"B. K. Abdullah, Zainab Basil Kadhim, Ghada Basil Kadhim, Zena Jameeel Ahmed","doi":"10.31031/nacs.2020.05.000619","DOIUrl":"https://doi.org/10.31031/nacs.2020.05.000619","url":null,"abstract":"Neuroblastoma is the most common malignancy in infancy and the third most common cancer in pediatric, following the acute leukemia and central nervous system tumor, constituting approximately 7-10% of pediatric malignancy. Most of the patients (approximately 90%) diagnosed before the age of 5 years, with peak incidence at the age of two years. However, the incidence of neuroblastoma decreasing with age and less than 5% from all cases diagnosed after the age of 10 years, its occurrence is rare during adulthood (one per 10 million cancer diagnoses per year). In addition, neuroblastoma is very rarely presented with Bone marrow involvement without identifiable primary site. We reported a young adult male patient with advanced neuroblastoma at the age of 21 with solely Bone marrow involvement without radiological identifiable primary tumor site who was died before starting him on chemotherapy treatment because of severe febrile neutropenia.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42885150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-15DOI: 10.31031/nacs.2020.05.000620
Aniket Adhikari
Tea considered as a mental stimulant, mood elevator and also advocated for oral cancer, is a national drink has been used in India. Consumption of black tea for the chemo preventive action has been shown to exert a protective effect against oral cancer [1]. The major polyphenol components of black tea (the fermented product) are theaflavins (1-3% dry weight) and thearubigins (10-40% dry weight). A study suggests that black-tea derived polyphenols also showed one of the chemo-preventive properties shown by green tea polyphenols.
{"title":"Therapeutic Effects of Black Tea on Micronuclei (Oral Cancer Biomarker) Induced by Betel Quid: A Mini Review","authors":"Aniket Adhikari","doi":"10.31031/nacs.2020.05.000620","DOIUrl":"https://doi.org/10.31031/nacs.2020.05.000620","url":null,"abstract":"Tea considered as a mental stimulant, mood elevator and also advocated for oral cancer, is a national drink has been used in India. Consumption of black tea for the chemo preventive action has been shown to exert a protective effect against oral cancer [1]. The major polyphenol components of black tea (the fermented product) are theaflavins (1-3% dry weight) and thearubigins (10-40% dry weight). A study suggests that black-tea derived polyphenols also showed one of the chemo-preventive properties shown by green tea polyphenols.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42206478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-08DOI: 10.31031/nacs.2020.05.000618
Irfan M Lone
In order to draw significant comparisons between the disparities in dealing with LGBT cancer patients in East and West, it becomes extremely essential for us, as clinicians and health care providers to understand the bigger picture of the LGBT Community in general. As we all know that in India we still have not been able to reach a point where all the people are accepted unconditionally; and when it comes to sexual orientation, we still face old taboos, socio-cultural and religious pressures, prejudice, and judgments in general. Moreover, while dealing with clients belonging to the LGBT community, clinicians also doesn’t have it easy. In India, we still do not approve same-sex marriages and the rights of the LGBT community are still not fully recognized, which puts this group on the lines of extreme vulnerability, both emotional and otherwise. On the other hand, the acceptance from family and friends, the government, and the general public and endless fear of ending up alone all life, makes things worse. However, thankfully the younger generation in India seems to be more accepting, possibly due to the social media explosion from last decade, or possibly due to easy access to worldwide web, mobile phones, and so on, and therefore, cultural and ideological exchanges with “online friends” abroad and also to some extent due to changing norms in Indian cinema.
{"title":"Impact of Cancer Diagnosis on Emotional Well Being and Quality of Life on Lgbt Population in India and Across Europe; A Report Drawn on the Bases on Experience and Birds Eye View of a Psycho-Oncologist","authors":"Irfan M Lone","doi":"10.31031/nacs.2020.05.000618","DOIUrl":"https://doi.org/10.31031/nacs.2020.05.000618","url":null,"abstract":"In order to draw significant comparisons between the disparities in dealing with LGBT cancer patients in East and West, it becomes extremely essential for us, as clinicians and health care providers to understand the bigger picture of the LGBT Community in general. As we all know that in India we still have not been able to reach a point where all the people are accepted unconditionally; and when it comes to sexual orientation, we still face old taboos, socio-cultural and religious pressures, prejudice, and judgments in general. Moreover, while dealing with clients belonging to the LGBT community, clinicians also doesn’t have it easy. In India, we still do not approve same-sex marriages and the rights of the LGBT community are still not fully recognized, which puts this group on the lines of extreme vulnerability, both emotional and otherwise. On the other hand, the acceptance from family and friends, the government, and the general public and endless fear of ending up alone all life, makes things worse. However, thankfully the younger generation in India seems to be more accepting, possibly due to the social media explosion from last decade, or possibly due to easy access to worldwide web, mobile phones, and so on, and therefore, cultural and ideological exchanges with “online friends” abroad and also to some extent due to changing norms in Indian cinema.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42960899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-20DOI: 10.31031/nacs.2020.05.000617
A. Bajaji
Elastofibroma dorsi is an uncommon, benign, subcutaneous, poorly circumscribed, nodular, preponderantly subscapular soft tissue neoplasm representing as a pseudo-tumour or a tumour-like lesion. The neoplasm is essentially composed of collagen and coarse, enlarged elastic fibres. Additionally, nomenclated as elastofibroma dorsi, the tumefaction can be contemplated as a reactive, mesenchymal hyperplasia with aberrant elastogenesis. Elastofibroma characteristically demonstrates elastic fibres intermixed with collagenous stroma and mature adipose tissue. Jarvi et al. [1] initially described the neoplasm in 1959 at the 12th congress of Scandinavian Pathologists. The condition was subsequently published in 1961 [1]. With anomalous imaging manifestations or doubtful tumour discernment, close monitoring, pertinent imaging or evaluation of cogent tissue specimen is recommended.
{"title":"The Malleable Mesenchyme- Elastofibroma","authors":"A. Bajaji","doi":"10.31031/nacs.2020.05.000617","DOIUrl":"https://doi.org/10.31031/nacs.2020.05.000617","url":null,"abstract":"Elastofibroma dorsi is an uncommon, benign, subcutaneous, poorly circumscribed, nodular, preponderantly subscapular soft tissue neoplasm representing as a pseudo-tumour or a tumour-like lesion. The neoplasm is essentially composed of collagen and coarse, enlarged elastic fibres. Additionally, nomenclated as elastofibroma dorsi, the tumefaction can be contemplated as a reactive, mesenchymal hyperplasia with aberrant elastogenesis. Elastofibroma characteristically demonstrates elastic fibres intermixed with collagenous stroma and mature adipose tissue. Jarvi et al. [1] initially described the neoplasm in 1959 at the 12th congress of Scandinavian Pathologists. The condition was subsequently published in 1961 [1]. With anomalous imaging manifestations or doubtful tumour discernment, close monitoring, pertinent imaging or evaluation of cogent tissue specimen is recommended.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47985995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-13DOI: 10.31031/nacs.2020.05.000616
B. Sharma
Recently invented several cancer immunotherapies that have succeeded with a diversity of new agents for clinical use. As such, notable progress immensely facilitated the designing of numerous effective immunotherapeutic regimens. Therapeutic vaccines and immune checkpoint blockade have lately demonstrated an enormous therapeutic efficacy thus generated great excitement for the development of new avenues on cancer treatments. Immunotherapies are highly potential to generate tumor-specific responses, as well as maintaining long-lasting remissions, unraveling vital approaches for future discoveries of cancer medicine. Next-generation cancer immunotherapies engaged with native mono-bi-specific antibodies are intended to target at innate immune checkpoints, conditional designing activated immune stimulator, redirecting Innate Cell Engagers (ICEs). Similarly, Natural killer cells are engineered for multi-specific immune targeting utilizing adaptable affinities and avidities, redirecting innate immune cells (dendritic, macrophages & NK cells). Oncolytic adenovirus-mediated targeting to alter cold tumors into hot including challenging tumor heterogeneity via interfering tumor sub-clonality are attractive projections to develop several novels immune-oncologic therapeutics towards personalized cancer medicine.
{"title":"Emerging Paradigm-Shifting in Cancer Immunotherapeutic Towards Personalized Cancer Medicine and Potential Challenges","authors":"B. Sharma","doi":"10.31031/nacs.2020.05.000616","DOIUrl":"https://doi.org/10.31031/nacs.2020.05.000616","url":null,"abstract":"Recently invented several cancer immunotherapies that have succeeded with a diversity of new agents for clinical use. As such, notable progress immensely facilitated the designing of numerous effective immunotherapeutic regimens. Therapeutic vaccines and immune checkpoint blockade have lately demonstrated an enormous therapeutic efficacy thus generated great excitement for the development of new avenues on cancer treatments. Immunotherapies are highly potential to generate tumor-specific responses, as well as maintaining long-lasting remissions, unraveling vital approaches for future discoveries of cancer medicine. Next-generation cancer immunotherapies engaged with native mono-bi-specific antibodies are intended to target at innate immune checkpoints, conditional designing activated immune stimulator, redirecting Innate Cell Engagers (ICEs). Similarly, Natural killer cells are engineered for multi-specific immune targeting utilizing adaptable affinities and avidities, redirecting innate immune cells (dendritic, macrophages & NK cells). Oncolytic adenovirus-mediated targeting to alter cold tumors into hot including challenging tumor heterogeneity via interfering tumor sub-clonality are attractive projections to develop several novels immune-oncologic therapeutics towards personalized cancer medicine.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44794678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-02DOI: 10.31031/NACS.2020.05.000614
V. Niculescu
Molecular biological investigations of the last decade have not been able to definitively determine the source of oncogenic transformation [1]. In recent years, the theory of carcinogenesis by CSCs has become increasingly plausible [2], but where do the CSCs come from? So far, the origin of CSCs has been obscure and controversial [3]. At first, CSCs and normal human stem cells hSCs seem to be strongly related. They have both the capacity for self-renewal and multilineage differentiation. Accordingly, CSCs were thought to originate from normal stem cell mutants, progenitor cell mutants or transiently amplifying cells of unregulated self-renewal ability [4]. Other researchers thought that CSCs originated from adult cells by de-differentiation [5-7] or by de-differentiation of mutated cells that create stem cell-like characteristics. In other words, a fully differentiated cell undergoes mutations or extracellular signals that drive it back to a stem-like state(a). Even today, the origin of CSCs is vague and ambiguous.
{"title":"Is Cancer Cell Reversion to Normalcy Possible? Un Update","authors":"V. Niculescu","doi":"10.31031/NACS.2020.05.000614","DOIUrl":"https://doi.org/10.31031/NACS.2020.05.000614","url":null,"abstract":"Molecular biological investigations of the last decade have not been able to definitively determine the source of oncogenic transformation [1]. In recent years, the theory of carcinogenesis by CSCs has become increasingly plausible [2], but where do the CSCs come from? So far, the origin of CSCs has been obscure and controversial [3]. At first, CSCs and normal human stem cells hSCs seem to be strongly related. They have both the capacity for self-renewal and multilineage differentiation. Accordingly, CSCs were thought to originate from normal stem cell mutants, progenitor cell mutants or transiently amplifying cells of unregulated self-renewal ability [4]. Other researchers thought that CSCs originated from adult cells by de-differentiation [5-7] or by de-differentiation of mutated cells that create stem cell-like characteristics. In other words, a fully differentiated cell undergoes mutations or extracellular signals that drive it back to a stem-like state(a). Even today, the origin of CSCs is vague and ambiguous.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48079923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-02DOI: 10.31031/NACS.2020.05.000613
Zemskov Vm, Neymann, Pronko Kn, Zemskov Am
It should be noted that the situation of progressive development of clinical immunology is currently quite complex and contradictory. The reason is the establishment of a new, fourth mechanism for the development of almost any, especially chronic diseases, i.e. immune disorders (deficiency states, auto aggressive reactions, hypersensitivity), as factors of their severity, as well as the formation of the necessary attributes of a new medical discipline, since the corresponding specialty has been approved, a network of medical institutions, scientific journals has been created, the production of a wide range of immunotropic drugs has been established, etc.).
{"title":"Some Aspects of the Problem of Progressive Development of Clinical Immunology","authors":"Zemskov Vm, Neymann, Pronko Kn, Zemskov Am","doi":"10.31031/NACS.2020.05.000613","DOIUrl":"https://doi.org/10.31031/NACS.2020.05.000613","url":null,"abstract":"It should be noted that the situation of progressive development of clinical immunology is currently quite complex and contradictory. The reason is the establishment of a new, fourth mechanism for the development of almost any, especially chronic diseases, i.e. immune disorders (deficiency states, auto aggressive reactions, hypersensitivity), as factors of their severity, as well as the formation of the necessary attributes of a new medical discipline, since the corresponding specialty has been approved, a network of medical institutions, scientific journals has been created, the production of a wide range of immunotropic drugs has been established, etc.).","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46839828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：